CD4 and neoplasm: MSC2-mediated alleviation of antigen-presenting capacity of tumor-infiltrating DCs resulted in unoptimal activation of naïve CD4+ and CD8+T lymphocytes which led to the reduced presence of effector CD4+Th1 and Th17 cells and CD8+CTLs in the tumors of B16F10+MSC14d-treated mice (Figure 4).